A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.

Phase 1 Recruiting 40 enrolled Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.

Timeline

Start: 2025-12-25
Primary completion: 2026-03
Completion: 2026-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HW211026	Unknown	—	Topical

A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.

Summary

Timeline

Drugs

Indications